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ABSTRACT: Formyl peptide receptor 2 (FPR2) plays important roles
in inﬂammation. In the present study, 20 analogues of the FPR2-selective
lipidated α-peptide/β-peptoid agonist Lau-[(S)-Aoc]-[Lys-βNPhe]6-
NH2 were generated, which allowed two novel subclasses of more
potent FPR2 agonists to be distinguished. Critical factors inﬂuencing
FPR2 recognition comprise the presence of β-peptoid phenylalanine-like
residues (i.e., βNPhe, βNspe, or βNrpe) in the peptidomimetic tail,
conﬁguration of the 2-aminooctanoic acid (Aoc) in the headgroup, and
the length of the N-terminal fatty acid. Intriguingly, a single βNrpe
residue in the vicinity of the N-terminus (i.e., Lau-[(S)-Aoc]-Lys-βNrpe-
[Lys-βNPhe]5-NH2) proved to increase the agonist potency, whereas the
βNspe-containing analogue was a weak FPR2-selective antagonist. Another subclass displaying potent agonism comprised
analogues possessing two α-amino acids vicinal to the headgroup. The optimized FPR2-activating lipidated peptidomimetics
exhibited biased signaling: PLC-PIP2-Ca
2+ signaling was activated, but without recruitment of β-arrestin or induction of
chemotaxis. These FPR2-interacting compounds are considered to be useful tools in future studies of receptor−ligand
interactions.
■ INTRODUCTION
Recruitment of neutrophils to inﬂammatory sites is directed by
host- or pathogen-derived danger molecules recognized by G-
protein-coupled receptors (GPCRs), for example, receptors for
platelet-activating factor (i.e., PAFR), adenosine triphosphate
(i.e., P2Y2R), and formyl peptide receptors FPR1 and FPR2.
The third FPR subclass (i.e., FPR3) is not expressed by human
neutrophils, and its biological functions are not yet known.1
FPRs are high-aﬃnity receptors for formyl peptides, being
danger molecules of bacterial and mitochondrial origin, albeit
these receptors also recognize a large number of non-
formylated peptides and small-molecule ligands, representing
diﬀerent chemical classes.2−4 FPRs are important not only for
neutrophil recruitment and initiation of inﬂammation but also
for resolution of such processes. Thus, aberrant FPR
expression is associated with a wide range of immunity-
mediated diseases, for example, atherosclerosis, cancer, neuro-
degeneration, and sepsis,5,6 and thus, FPRs constitute attractive
therapeutic targets. Consequently, an increasing number of
FPR ligands with therapeutic potential have been identiﬁed
and characterized in recent years.3,4
A major complication in therapeutic use of peptide-based
ligands is their intrinsic susceptibility to in vivo degradation by
peptidases, conferring low bioavailability. Hence, peptidomi-
metics (partly composed of non-natural residues) that resist
enzymatic degradation constitute favorable alternatives. Stable
α-peptide/β-peptoid hybrid oligomers displaying an alternating
design with cationic α-amino acids and aromatic hydrophobic
β-peptoid residues (Figure 1) have been found to mimic the
biological activities of peptides, such as microbial killing,
reduction of bioﬁlm formation, and immunomodulation. This
class of peptidomimetics has proved to constitute a promising
source of lead compounds for the development of potential
pharmaceuticals within these therapeutic areas.7−9
FPRs belong to the superfamily of GPCRs that mediate
fundamental cellular responses upon agonist binding, with
subsequent G-protein-dependent signal transduction.6 Both
pro- and anti-inﬂammatory responses are mediated by FPRs,5
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and this dual functionality appears to be in line with the
“biased signaling” concept, often termed “functional selectiv-
ity”.10,11 Classically, activation of a GPCR signaling pathway
initiates the dissociation of a heterotrimeric G-protein,
triggering production of multiple downstream secondary
messengers, for example, phospholipases and protein kinases.
The resulting signaling cascade is terminated by recruitment of
β-arrestin to the GPCR, a coupling that sterically blocks further
G-protein recruitment/signaling.12 Recent research has high-
lighted that β-arrestins, besides this involvement in termi-
nation, also possess a G-protein-independent signaling
capacity.13,14 The concept of biased signaling states that a
certain ligand may selectively activate one (or a few) of several
signaling pathways possible for a given receptor: that is, an
activated receptor may induce signals both downstream from
the G-protein and downstream from β-arrestin, or signaling
may only occur through one of these pathways.10,15 In line
with this, we have recently shown that an FPR2-selective
agonist, F2Pal10, belonging to the pepducin-type lipopeptides,
in fact is a biased FPR2 agonist that activates PLC-PIP2-Ca
2+
signaling and assembly of the superoxide-generating nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase in
the absence of β-arrestin recruitment.16 We have earlier
identiﬁed both neutrophil-inhibiting and -activating lipidated
peptidomimetics (e.g., 1 and 2, respectively; Figure 2), for
which it was shown that FPR2 is the preferred receptor. The
presence of a hydrophobic N-terminal headgroup as well as the
β-peptoid units in the tail moiety were essential for the
biological activities of these lipidated peptidomimetics.17−19
Nevertheless, several structural features of these ligands remain
to be investigated in order to delineate the more precise
requirements for the optimal interaction with FPRs, in
particular, the factors determining whether an agonistic or
inhibitory receptor-selective outcome results from the
interaction.
A major purpose of the present study was identiﬁcation of
structural determinants in lipidated α-peptide/β-peptoid
hybrid peptidomimetics that are of importance for the FPR2-
dependent activation of neutrophils by agonists resembling
compound 2. This included comparison of the FPR2
interaction of 2 with that of 3 known and 20 novel analogues
(i.e., 3−25). The present structure−function optimization of
compound 2, a previously described cross-species FPR2
agonist, resulted in identiﬁcation of two subclasses of more
potent FPR2 agonists. The full agonistic activity was found to
rely not only on the presence of a fatty acid of appropriate
length and the stereochemistry of the adjacent 2-amino-
octanoic acid (Aoc) residue, but also on the nature of the two
vicinal residues as well as the presence/absence of α-chirality
in the peptoid residues of the tail region. Moreover, our data
disclose a propensity for biased signaling of FPR2 agonists
belonging to this class of lipidated peptidomimetics that trigger
the PLC-PIP2-Ca
2+ signaling pathway without recruitment of
β-arrestin or induction of chemotaxis.
■ RESULTS AND DISCUSSION
Introduction of α-Chiral β-Peptoid Units Inﬂuences
the Type of Activity and Potency. Through screening of a
focused library of lipidated α-peptide/β-peptoid hybrids, Lau-
[(S)-Aoc]-[Lys-βNPhe]6-NH2 (2; Figure 2) was previously
identiﬁed as the ﬁrst FPR2-selective peptidomimetic agonist,
and the FPR2 preference was conﬁrmed by using FPR2
overexpressing cells.17 Compound 2 is a partial FPR2 agonist
that induces release of superoxide with a slightly lower potency
and eﬃcacy in comparison to that of the prototypical peptide
FPR2 agonist WKYMVM.17 Incorporation of shorter or longer
N-terminal fatty acids (to give 3 or 4, respectively; Table 2)
resulted in reduced or unaﬀected potency as compared to that
of 2, while FPR2 activation proved to be dependent on an (S)-
conﬁgurated N-terminal Aoc residue.17 These ﬁndings
prompted us to investigate the inﬂuence of chirality in other
parts of the molecule, and therefore, several analogues were
designed as depicted in Figure 2.
Introduction of chirality in the β-peptoid unit by
incorporation of βNrpe (to give 5) conferred increased eﬃcacy
in triggering superoxide release because 5 induced a higher
maximum response, but similar eﬃcacy when compared to the
response induced by WKYMVM, and is therefore considered
to be a full agonist for the receptor (Figure 3A, and Supporting
Information, Figure S1). Furthermore, analysis of the dose−
response curves showed that compound 5 is ∼3-fold more
potent than 2, with EC50 values of 58 nM (95% CI: 51−66)
and 167 nM (95% CI: 142−197), respectively (Figure 3B).
The response induced by compound 5 was mediated through
FPR2 as inferred by the inhibition proﬁles, obtained when
applying well-characterized selective FPR1 and FPR2 antago-
nists (see the list of prototypical ligands in Table 1). Thus, the
activity of 5 was completely abolished by preincubation with
two FPR2-selective antagonists, i.e., PBP10 and the earlier
identiﬁed peptidomimetic inhibitor 1 (Figure 4A,B). In
contrast, the FPR1-selective antagonist cyclosporine H
(CysH) did not inﬂuence the response induced by 5.
Furthermore, the FPR2 selectivity of 5 was conﬁrmed by
receptor desensitization experiments, showing that neutrophils
activated by the FPR2 agonist WKYMVM were desensitized to
a subsequent dose of 5 and of WKYMVM. In contrast,
neutrophils stimulated by fMLF were fully responsive to a
subsequent dose of 5 but not to fMLF (Figure 4C,D).
The inﬂuence of peptoid stereochemistry on activity was
further investigated by examining analogue 8 in which the α-
chiral βNrpe peptoid residues were replaced by βNspe units,
Figure 1. Nomenclature of structural units in the peptidomimetics
investigated.
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displaying the opposite side-chain stereochemistry (see Figure
1). Interestingly, 8 lacked the ability to confer activation of
neutrophil NADPH oxidase (Figure 5A). Generally, the level
of superoxide released by neutrophils depends on the cellular
state examined, being either naiv̈e (i.e., low-responding) or
primed (i.e., high-responding). The activity of 8 was examined
on cells in the primed state, achieved by incubating naiv̈e cells
with tumor necrosis factor-α (TNF-α) for 20 min at 37 °C. No
Figure 2. Chemical structures of peptidomimetics investigated as potential FPR2 agonists.
Figure 3. Compound 5 activates human neutrophil NADPH oxidase as a full agonist. The production of superoxide anions was measured by an
isoluminol-enhanced chemiluminescence system (see Experimental Section). Neutrophils (105 cells/mL) were preincubated (5 min at 37 °C) and
then stimulated by compound 2 or 5, after which the release of superoxide anions was recorded continuously. (A) Representative response curves
out of at least three independent experiments for compounds 2 and 5 (at 500 and 250 nM, respectively, that give maximal response). Abscissa: time
of study (min); ordinate: superoxide production (106 × counts/min; Mcpm). (B) Dose-dependent superoxide release induced by compounds 2
and 5. Data are presented as normalized peak response values (mean ± SD; n = 3 for compound 5, and n = 5 for compound 2), which diﬀer
between the two compounds (see subﬁgure A). The graph furthermore shows the ﬁtted curve as well as the calculated EC50 (95% CI).
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superoxide release was inducible by 8 from such primed cells
(Figure 5A), thus further conﬁrming the lack of agonistic eﬀect
of 8.
Our experience gained from the work on FPR2-interacting
lipopeptides belonging to the pepducin family suggests that
subtle structural modiﬁcation, for example, a single exchange of
an amino acid, may result in a switch of FPR2 ligands from
agonist to antagonist.25,26 On this basis, the inhibitory eﬀect of
8 on FPR2 was examined, showing that 8 dose-dependently,
but incompletely, inhibited the response generated by the
FPR2-selective agonist WKYMVM with an IC50 value of 0.29
μM (CI: 0.22−0.37 μM; Figure 5B and inset herein). The
ability of peptidomimetic 8 to produce a transient increase in
the concentration of cytosolic Ca2+, a very early downstream
signaling event following FPR activation, was also investigated.
Expectedly, 8 proved unable to trigger a transient Ca2+
response by itself. The receptor preference of 8 for FPR2
over FPR1, measured as its inhibitory eﬀect in the NADPH
oxidase assay, was conﬁrmed because 8 also blocked the
WKYMVM-induced Ca2+ transient (Figure 5C). By contrast,
the transient increase in the intracellular calcium level, induced
by the FPR1-selective agonist fMLF, was not inﬂuenced by the
presence of 8 (Figure 5C inset).
Inﬂuence of Fatty Acid Length and Stereochemistry
of the Aoc Residue in the Headgroup. Interestingly, while
the size of the N-terminal fatty acid moiety was of minor
importance for the parent compound 2, replacement of the N-
terminal lauric acid in 5 with the shorter decanoic acid (to give
6) decreased potency, while a two-carbon increased length of
the fatty acid (to give 7) led to a ∼2-fold increased potency
(Table 2). In addition, the structural requirements for
agonism/antagonism of analogues of 8, displaying diﬀerent
lengths of N-terminal fatty acids (i.e., 9 and 10), were
examined, but neither 9 nor 10 induced any release of
superoxide in neutrophils, demonstrating their lack of agonistic
eﬀects, while they retained a weak FPR2-selective antagonistic
proﬁle like the parent 8 (Table 2). The highest antagonist
Table 1. Established FPR Ligands Used in the Present Study
and Their Activity Proﬁle
name activity and receptor selectivity references
WKYMVM FPR2 agonist 20
fMLF FPR1 agonist 21,22
PBP10
a FPR2 antagonist 23
CysHb FPR1 antagonist 24
aRhB-QRLFQVKGRR-OH, where RhB = rhodamine B. bCysH =
cyclosporine H.
Figure 4. Production of O2
− in neutrophils induced by compound 5 is mediated via FPR2. (A) Neutrophils (105 cells/mL) were preincubated (5
min at 37 °C) with the FPR2-selective inhibitors PBP10 (1 μM) or compound 1 (1 μM) or with the FPR1-selective inhibitor CysH (1 μM) prior to
stimulation with compound 5 (250 nM), and then the production of superoxide anions was recorded continuously. Abscissa: time of study (min);
ordinate: superoxide production (106 × counts/min; Mcpm). A representative data set obtained from at least three independent experiments (n ≥
3) is shown. (B) Inhibition of production of O2
− induced by compound 5 in human neutrophils. Neutrophils (105 cells/mL) were preincubated (5
min at 37 °C) with or without receptor-selective antagonist (CysH for FPR1, 1 μM; PBP10 or compound 1 for FPR2, 1 μM). The cells were then
stimulated with compound 5 (250 nM), and then the O2
− production was measured over time. The results are presented as normalized to the
response induced by compound 5 in the absence of an inhibitor (determined as the amount of O2
− produced; peak value). The statistical
signiﬁcance was calculated with one-way ANOVA using Dunnett’s multiple comparisons test against control that received no inhibitor (mean ±
SD; n = 3), ***p < 0.001. (C) Neutrophils (105 cells/mL) were prewarmed (5 min at 37 °C) before stimulation with WKYMVM (100 nM) or
fMLF (100 nM). When the response had declined to baseline, a subsequent stimulation with compound 5 (250 nM) on the same cells was
performed (as indicated by the second arrow). The response from naıv̈e neutrophils treated with compound 5 (buﬀer control) is shown for
comparison. Abscissa: time of study (min); ordinate: superoxide production (106 × counts/min; Mcpm). (D) Neutrophils (105 cells/mL) were
prewarmed (5 min at 37 °C) before stimulation with WKYMVM (100 nM, solid line) or fMLF (100 nM, dashed line). When the responses had
declined to baseline, a subsequent stimulation with WKYMVM (100 nM) or fMLF (100 nM) on the same cells was performed (as indicated by the
second arrow). A representative data set is shown of at least three independent experiments (i.e., n ≥ 3).
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concentration tested was 1 μM, at which inﬂection of the
inhibition curve was not observed. By contrast, our earlier
published closely related but strongly antagonistic peptidomi-
metics (e.g., 1) had IC50 values in the range 50−100 nM.18
Consequently, the antagonistic analogues, identiﬁed in the
present work, were considered to display only weakly
antagonistic properties. Hence, on the basis of these ﬁndings,
the stereochemistry of the peptoid units appears to be a most
critical determinant of the type of FPR2 interaction displayed
by this class of peptidomimetic ligands, but notably FPR2
selectivity is retained for all these peptidomimetic analogues
(i.e., 2−10).
The precise function of the N-terminal fatty acid moiety in
the FPR2 interaction is not clear, but many lipidated molecules
are modulators of FPR2 function, and these include the FPR2-
modulating pepducins.5 For pepducins, suggested to mediate
their modulating action on the intracellular signaling domains
of the targeted receptor, the fatty acid is considered to enable
peptide translocation across the lipid bilayer.27,28 This concept
may well apply to other GPCR-derived pepducins that interact
with their respective receptors, but the mode of action of
FPR2-activating/inhibiting pepducins appears to be unique
because recent results infer that they interact with extracellular
receptor parts. This issue has been discussed in detail in earlier
publications.6,16,25,29 This pattern recognition model is
supported by the ﬁnding that lipidated peptidomimetics also
preferentially display aﬃnity for FPR2 on the cell surface.17,18
Nevertheless, when only an N-terminal fatty acid is present on
a peptidomimetic tail or the headgroup (N-acylated Aoc) is
conjugated to an α-peptide/β-peptoid tail sequence possessing
inappropriate chirality of the hydrophobic β-peptoid side
chains, the resulting compounds lack agonistic eﬀects on
neutrophils, showing that interactions of the peptidomimetic
tail sequence also contribute to FPR2 agonism.17−19
In line with our previous results for compound 2, the
stereochemistry of the Aoc residue was also of utmost
importance for both type and degree of activity. Thus,
compounds 11 and 12, both displaying an (R)-Aoc residue
instead of (S)-Aoc present in 5 (Table 2), were almost devoid
of neutrophil-activating eﬀect. On the other hand, for
antagonistic analogues, the stereochemistry of the Aoc residue
did not substantially aﬀect the activity (i.e., 13 vs 8, Table 2).
Collectively, these ﬁndings suggest that the functional
groups displayed by the peptidomimetic tail and the headgroup
residues all interact with sites within FPR2, which, depending
on the degree of the ﬁt, will result in activation or inhibition.
The latter most likely arise from a slight deviation from the
optimal orientation of one or more crucial functional groups in
an antagonistic ligand that, despite lack of ability to induce the
conformational change associated with activation, blocks
binding of agonists or locks the receptor in an inactive
conformation.
Substitutions Vicinal to the N-Terminal Hydrophobic
Headgroup Alter Activity and Potency. The quite speciﬁc
Figure 5. Peptoid backbone stereochemistry is critical for agonist/antagonist activity. (A) Naiv̈e neutrophils (105 cells/mL) or neutrophils
pretreated with TNF-α (for 20 min at 37 °C) were preincubated (5 min at 37 °C), and were then stimulated with compound 8 (1 μM).
Subsequently, the release of superoxide anions was recorded continuously. Abscissa: time of study (min); ordinate: superoxide production (106 ×
counts/min; Mcpm). A representative data set from at least three independent experiments (i.e., n ≥ 3) is shown. (B) Neutrophils (105 cells/mL)
were preincubated (5 min at 37 °C) with or without compound 8 (1 μM), and were then stimulated with WKYMVM (100 nM). Subsequently, the
release of superoxide anions was recorded continuously. Abscissa: time of study (min); ordinate: superoxide production (106 × counts/min;
Mcpm). A representative data set from at least three independent experiments (i.e., n ≥ 3) is shown. The inset shows an inhibitory dose−response
curve for compound 8. Data are presented as the normalized peak response (mean ± SD; n = 3), together with the ﬁtted curve and the calculated
IC50 value (95% CI). (C) The intracellular calcium transient was measured in neutrophils labeled with Fura-2. Cells were preincubated (10 min at
37 °C) with or without compound 8 (1 μM), and were then stimulated with WKYMVM (10 nM), after which the concentration of free
intracellular calcium was measured by the Fura-2 ﬂuorescence. Inset: Cells were preincubated (10 min at 37 °C) with or without compound 8 (1
μM), and were then stimulated with fMLF (10 nM). Abscissa: time of study (s); ordinate: ﬂuorescence (arbitrary units). A representative data set
from at least three independent experiments (i.e., n ≥ 3) is shown.
ACS Omega Article
DOI: 10.1021/acsomega.9b00098
ACS Omega 2019, 4, 5968−5982
5972
requirements for both the fatty acid and Aoc residues for FPR2
activation infer that the entire N-terminal headgroup is indeed
involved in crucial ligand−receptor interactions initiating
signaling. In accordance with this, even small changes to the
Lau-(S)-Aoc headgroup, characteristic of potent peptidomi-
metic agonists, give rise to analogues with weakened agonistic
or even antagonistic properties.17 In the present study, an
additional aim was to investigate whether the residues vicinal
to the hydrophobic headgroup constitute potential sites for
further optimization of agonist−receptor interactions. Initially,
analogues were designed to display variation only in the
stereochemistry of the ﬁrst β-peptoid unit (i.e., replacement of
the vicinal βNPhe in 2 with βNrpe or βNspe to give 14 and 15,
respectively), while retaining achiral βNPhe units in the C-
terminal region of the peptidomimetic tail. Compared to 5,
analogue 14 retained full activation potential, and its potency
was higher (Table 2 and Figure 6). Importantly, 14 retained
FPR2 preference as shown by the fact that the FPR2-selective
antagonist PBP10 but not the FPR1-speciﬁc antagonist
cyclosporin H inhibited its activity (as shown for PBP10 in
Figure 6A). The response was of the same order of magnitude
as that of the FPR2 agonist WKYMVM (Figure 6B), but in
contrast to WKYMVM, the neutrophil-activating eﬀect of
compound 14 was not aﬀected by myeloperoxidase (MPO)-
derived reactive oxygen species (Figure 6C). Peptidomimetic
14 thus shows better oxidative stability than the conventional
peptide agonist.
These data indeed infer that interactions with several
functional groups in the N-terminal part of the peptidomimetic
tail region are involved in mediating FPR2 activation. In
support of this hypothesis, introduction of a single βNspe in
this position (to give 15) proved suﬃcient to abolish its
capability for FPR2 activation. Nonetheless, the ability of 15 to
inhibit the WKYMVM response was lowered (Table 2),
suggesting that other groups contribute more to the propensity
for inhibition.
Thus, the data obtained so far indicate the importance of
functional groups within the N-terminal headgroup and in the
residues adjacent to this (i.e., Lau-[(S)-Aoc]-Lys-X; with X =
βNrpe conferring highest potency) in the activation of FPR2
by such peptidomimetics. In order to investigate the nature of
these interactions further, we prepared a series of variants of 2,
in which the lysine and/or the βNPhe residues in the extended
headgroup were replaced by α-amino acids with diﬀerent but
related functional groups. Replacement of the ﬁrst βNPhe in 2
with the corresponding α-amino acid Phe (resulting in 16) had
no signiﬁcant eﬀect on the relative potencies [EC50 of 167 nM
(95% CI: 142−197) and 140 nM (95% CI: 117−163) for 2
and 16, respectively]. In contrast, similar replacement with Tyr
(to give 17) further increased the potency [to an EC50 of 49
nM (95% CI: 45−53)], while substitution with Trp (to give
18) led only to a slightly reduced potency [EC50 of 208 nM
(95% CI: 134−321); Table 2]. These data suggest that the
hydrophobic functional group in the side chain of the residue
in this position is involved in the receptor interaction
Table 2. Compounds Tested for FPR2 Interaction by Using the NADPH Oxidase Activation Assay
no. sequence
EC50 nM
(CI) comment ref
Variation of Fatty Acid and Peptoid Chirality
2 Lau-[(S)-Aoc]-[Lys-
βNPhe]6-NH2
167
(142−197)
partial agonista,b 17
3 Dec-[(S)-Aoc]-[Lys-
βNPhe]6-NH2
≫> 200 partial agonista,b 17
4 Myr-[(S)-Aoc]-[Lys-
βNPhe]6-NH2
176
(153−202)
partial agonista 17
5 Lau-[(S)-Aoc]-[Lys-
βNrpe]6-NH2
58 (51−66) full agonist
6 Dec-[(S)-Aoc]-[Lys-
βNrpe]6-NH2
177
(138−226)
partial agonist
7 Myr-[(S)-Aoc]-[Lys-
βNrpe]6-NH2
35 (25−45) full agonist
8 Lau-[(S)-Aoc]-[Lys-
βNspe]6-NH2
antagonistc IC50
= 0.29 μM
(0.22−0.37)
9 Dec-[(S)-Aoc]-[Lys-
βNspe]6-NH2
weak antagonistd
10 Myr-[(S)-Aoc]-[Lys-
βNspe]6-NH2
weak antagonistd
Variation of Aoc Stereochemistry
11 Lau-[(R)-Aoc]-[Lys-
βNPhe]6-NH2
too weake agonist 17
12 Lau-[(R)-Aoc]-[Lys-
βNrpe]6-NH2
too weake agonist
13 Lau-[(R)-Aoc]-[Lys-
βNspe]6-NH2
weak antagonistd
Variation of Peptoid Residue Adjacent to Headgroup
14 Lau-[(S)-Aoc]-Lys-
βNrpe-[Lys-
βNPhe]5‑NH2
29 (22−37) full agonist
15 Lau-[(S)-Aoc]-Lys-
βNspe-[Lys-βNPhe]5-
NH2
weak antagonistd
no. sequence
EC50 nM
(CI) comment ref
Insertion of Hydrophobic Amino Acid (Instead of β-Peptoid) Adjacent to
Headgroup
16 Lau-[(S)-Aoc]-Lys-Phe-
[Lys-βNPhe]5-NH2
140
(117−163)
full agonist
17 Lau-[(S)-Aoc]-Lys-Tyr-
[Lys-βNPhe]5-NH2
49 (45−53) full agonist
18 Lau-[(S)-Aoc]-Lys-Trp-
[Lys-βNPhe]5-NH2
208
(134−321)
partial agonista
Replacement of Lys Adjacent to Headgroup
19 Lau-[(S)-Aoc]-Dab-
βNPhe-[Lys-βNPhe]5-
NH2
weak antagonistd
20 Lau-[(S)-Aoc]-Dab-Phe-
[Lys-βNPhe]5-NH2
weak antagonistd
21 Lau-[(S)-Aoc]-(D-Lys)-
Phe-[Lys-βNPhe]5-NH2
weak antagonistd
22 Lau-[(S)-Aoc]-βNLys-
Phe-[Lys-βNPhe]5-NH2
weak antagonistd
24 Lau-[(S)-Aoc]-Nle-Phe-
[Lys-βNPhe]5-NH2
87 (76−105) full agonist
FPR2 > FPR1
25 Lau-[(S)-Aoc]-Arg-Phe-
[Lys-βNPhe]5-NH2
45 (42−49) full agonist
Reversed Backbone
23 Lau-[(S)-Aoc]-(βNLys-
Phe)6-NH2
weak antagonistd
aDeﬁned as signiﬁcant lower max response (in O2
− production) than
that induced by WKYMVM (Supporting Information, Figure S1).
bEmax values are provided in ref 17 and in Supporting Information,
Figure S1. cDetermined by the inhibition of the O2
− production
induced by WKYMVM. dInhibitory activity but no IC50 could be
determined because inﬂection of the dose−response curve was not
achieved at the highest concentration tested (1 μM). eActivation of
superoxide release was observed, but the inﬂection point of the dose−
response curve was not reached at the maximum concentration tested
(1 μM), and thus no EC50 value could be determined.
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promoting activation, albeit some polarity appears to be
preferable in this position.
Furthermore, replacement of the N-terminal lysine in 2 or
16 with (S)-2,3-diaminobutanoic acid (Dab), having a two-
carbon shorter side chain (to give 19 or 20), abrogated all FPR
activation when the adjacent hydrophobic residue was Phe or
βNPhe; however, the resulting analogues exhibited weak
antagonistic properties. Likewise, replacement of this Lys
with D-Lys or βNLys, conferring altered or absence of chirality
(in the resulting 21 or 22), respectively, also led to a loss of
agonistic activity. However, in line with previous minor
modiﬁcations of 2, these molecules possessed inhibitor/
antagonistic properties, implying that the cationic Lys adjacent
to Aoc is also directly involved in receptor interactions.
Moreover, analogue 23 displaying a completely reversed design
with alternating cationic β-peptoid residues (i.e., βNLys units)
and hydrophobic Phe residues proved to possess only weak
FPR2-antagonistic properties. In compound 24, the ﬁrst Lys
was replaced by the noncharged Nle, which increased its
potency almost 2-fold as compared to that of 16. Interestingly,
the receptor selectivity of 24 was reduced, as it activated both
FPR1 and FPR2. This was evident from the observation that in
order to achieve full inhibition of the response induced by 24,
the antagonists CysH (FPR1-selective) and PBP10 (FPR2-
selective) had to be employed in combination (Supporting
Information, Figure S2). Analogue 25, displaying a Lys → Arg
substitution (and thus a slightly elongated cationic side chain),
possessed a ∼3-fold increased potency as compared to that of
16, while retaining FPR2 selectivity (Table 2).
These structure−activity relationships indicate that chirality
as well as length and charge of the side chain in the residue
adjacent to Aoc inﬂuences the ability of the analogue to
activate FPRs. Noticeably, charge determines whether the
analogue exhibits full selectivity for FPR2 over FPR1. These
ﬁndings correspond well with recent results obtained in a
combined mutagenesis/computer modeling study, showing
that the primary diﬀerence between FPR1 and FPR2, regarding
their respective orthosteric binding sites for formyl peptides,
relates to their electrostatic potential: the binding site in FPR2
is negatively charged because of the presence of an Asp in
position 281, whereas FPR1 contains a neutral Gly in the same
position.30
Pronounced FPR2 Reactivation via Cross-Talk with
the Receptors for PAF and ATP in Peptidomimetic-
Desensitized Neutrophils. During infection/inﬂammation,
microbes or damaged host cells release several danger
Figure 6. (A) Compound 14 is a highly potent FPR2-activating peptidomimetic. Neutrophils (105 cells/mL) were preincubated (5 min at 37 °C)
with the FPR2-selective inhibitor PBP10 (1 μM) or buﬀer before stimulation with compound 14 (100 nM), and then the production of superoxide
anions was recorded continuously. Abscissa: time of study (min); ordinate: superoxide production (106 × counts/min; Mcpm). A representative
data set out of three independent experiments (n = 3) is shown. Inset: Dose-dependent superoxide release induced by compound 14; data are
presented as normalized peak response (mean ± SD; n = 3), and the ﬁtted curve as well as the EC50 value and 95% conﬁdence interval are
calculated. (B) Neutrophils (105 cells/mL) were preincubated for 5 min at 37 °C, and were then stimulated with compound 14 (1 μM) or
WKYMVM (100 nM), and then release of superoxide anions was recorded continuously. Abscissa: time of study (min); ordinate: superoxide
production (106 × counts/min; Mcpm). A representative data set out of three independent experiments (n = 3) is shown. Inset: Comparison of the
responses induced by compound 14 and WKYMVM is presented as the ratio between the peak values obtained with compound 14 and
WKYMVM, respectively (mean ± SD; n = 3). (C) Compound 14 is not sensitive to oxidation by the MPO−H2O2 system. The peptide WKYMVM
(1 μM) and compound 14 (1 μM) were incubated with MPO (1 μg/mL) and H2O2 (10 μM). The remaining activity of the agonists (WKYMVM
and compound 14 after 100× dilution in the oxidase-measuring system) was determined by their ability to activate the neutrophil NADPH oxidase.
Neutrophils (105 cells/mL) were activated with untreated and MPO−H2O2-treated compound 14 (100 nM ﬁnal concentration) or WKYMVM
(100 nM ﬁnal concentration), and then the peaks of the responses were determined. The remaining activation potencies are presented as the
percentage relative to the responses induced by the untreated agonists (controls) and treated agonists (mean ± SD; n = 3). Statistical analysis was
performed by using paired Student’s t-test, **p < 0.01).
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molecules/chemoattractants, including formyl peptides that
are sensed by neutrophils through surface-expressed GPCRs.6
These receptors cross-talk through diﬀerent mechanisms and
together they regulate neutrophil directional migration and
other eﬀector responses.31,32 Previously, it was found that upon
desensitization FPR2 may be reactivated by receptor cross-talk
Figure 7. Neutrophils desensitized with compound 14 can be reactivated by PAF to a greater extent than neutrophils desensitized with WKYMVM.
(A) Neutrophils (105 cells/mL) were ﬁrst desensitized with compound 14 (250 nM) and subsequently stimulated with PAF (100 nM; as indicated
by the arrow: solid line), and then release of superoxide anions was recorded continuously. In one sample, the FPR2-selective inhibitor PBP10 (1
μM) was added 1 min prior to PAF stimulation (dashed line). The PAF responses induced in naiv̈e cells (dotted line) are shown for comparison. A
representative data set out of three independent experiments (n = 3) is shown. Inset: Neutrophils (105 cells/mL) were ﬁrst desensitized with
compound 14 (250 nM) and subsequently stimulated with ATP (50 μM; as indicated by the arrow: solid line). The ATP (50 μM) responses
induced in naiv̈e cells (dashed line) are shown for comparison. Abscissa: time of study (min); ordinate: superoxide production (106 × counts/min;
Mcpm). (B) Neutrophils (105 cells/mL) were ﬁrst desensitized with compound 14 (250 nM; solid line) or WKYMVM (100 nM; dashed line) and
subsequently stimulated with PAF (100 nM; as indicated by the arrow), and then release of superoxide anions was recorded continuously. Abscissa:
time of study (min); ordinate: superoxide production (106 × counts/min; Mcpm). A representative data set out of three independent experiments
(n = 3) is shown.
Figure 8. Compound 14 dose-dependently induces an intracellular calcium transient but no β-arrestin recruitment. (A) Intracellular calcium
transient was measured in neutrophils loaded with Fura-2. Cells were preincubated (10 min at 37 °C) and then stimulated with compound 14 in
diﬀerent concentrations (50, 25, and 10 nM) or (B) with WKYMVM (10, 5, and 1 nM), after which the concentration of free intracellular calcium
was measured by the Fura-2 ﬂuorescence. Abscissa: time of study (s); ordinate: ﬂuorescence (arbitrary units). Representative data sets out of three
independent experiments (n = 3) are shown in A and B. (C/D) FPR2-induced β-arrestin translocation was measured in PathHunter CHO cells
from DiscoverX that coexpressed prolinked FPR1/FPR2 and β-galactosidase. Binding of β-arrestin was quantiﬁed by ﬂuorescence through enzyme
complementation. The prototypic FPR1 agonist fMLF (100 and 10 nM) induced β-arrestin translocation in FPR1-overexpressing cells, whereas the
FPR2 agonist WKYMVM (100 and 25 nM) induced β-arrestin translocation in FPR2-overexpressing cells. In contrast, peptidomimetic 14 (at 250
and 100 nM) failed to induce any β-arrestin translocation in both cell lines. Data are expressed as mean ± SD from three independent experiments
(i.e., n = 3). The statistical signiﬁcance was calculated with one-way ANOVA using Dunnett’s multiple comparison test against the buﬀer control.
**p < 0.001.
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induced by ATP or PAF upon binding to their respective
receptors. The molecular origin of this cross-talk reactivation is
not clear, but we have shown that the reactivation signaling
pathway bypasses the PLC-PIP2-Ca
2+ signal generated down-
stream of the receptors.33 To determine the ability of PAF and
ATP to reactivate peptidomimetic-desensitized FPR2 (for
more details about the receptor cross-talk reactivation process,
see refs32−36), neutrophils desensitized with 14 were subjected
to reactivation through addition of PAF (an agonist for PAFR)
or ATP (an agonist for P2Y2R). The PAF-induced response
was primed in comparison to the response induced in naiv̈e
cells (Figure 7A). In agreement with a cross-talk mechanism
for reactivation of FPR2, the PAF-induced response proved
sensitive to the FPR2-selective antagonist PBP10 when this was
added prior to stimulation with PAF (Figure 7A). A very
similar reactivation pattern was observed when PAF was
replaced with ATP that activates the neutrophil P2Y2R (Figure
7A inset). More importantly, when the cross-talk reactivation
in neutrophils desensitized with 14 was compared to that
observed for cells desensitized with the conventional peptide
FPR2 agonist WKYMVM, the response was substantially
higher in cells desensitized with 14 (Figure 7B). A higher
concentration of WKYMVM proved not to compensate for the
increased potency of 14 in cross-talk reactivation. We have
shown earlier that PAF/ATP is also capable of potent
reactivation of neutrophils desensitized with FPR2-selective
lipopeptides belonging to the pepducin family of GPCR-
activating agonists,34,35 suggesting similarities between the
signaling induced by FPR2-selective pepducins and lipidated
peptidomimetics.
FPR2-Selective Peptidomimetics Trigger the Calcium
Signaling Pathway without Recruitment of β-Arrestin.
Signaling induced by the FPR2-selective neutrophil-activating
pepducin (F2Pal10) was recently shown to be biased toward
activation of the PLC-PIP2-Ca
2+ pathway, while β-arrestin was
not recruited.16 The β-arrestin signaling pathway cannot be
quantitatively determined in neutrophils, and therefore, the
PathHunter enzyme fragment (EA) complementation tech-
nology in FPR-overexpressing CHO cells was used to compare
the signaling properties of 14 with those of the conventional
FPR2-selective agonist WKYMVM.
At concentrations of 25 and 50 nM, compound 14 evoked a
transient increase in intracellular Ca2+ level in neutrophils
(Figure 8A), whereas WKYMVM at concentrations of 5 and
10 nM induced a similar concentration-dependent increased
Ca2+ level (Figure 8B). Expectedly, fMLF (at 10 nM) only
triggered β-arrestin recruitment in FPR1-overexpressing cells
because of its FPR1 selectivity (Figure 8C,D), while neither
WKYMVM nor compound 14 aﬀected these cells (Figure 8C).
From the β-arrestin translocation experiments with FPR2-
Figure 9. Compound 14 neither competes with the FPR2 agonist WKYMVM for binding nor induces neutrophil migration. (A) No competitive
inhibition of binding of the conventional FPR2 agonist WKYMVM is mediated by compound 14. Neutrophils (106 cells/mL) were incubated (10
min on ice) without any additive (control to determine total binding) and with WKYMVM (100 nM) or compound 14 (100 nM−1 μM), after
which the ﬂuorescently labeled FPR2-selective agonist Cy5-WKYMVM (1 nM) was added, and then incubation was continued for 60 min. The
results showed remaining ﬂuorescence activity in the presence of nonlabeled WKYMVM or compound 14 as compared to total binding expressed
in percent of the value for the control (mean ± SD, n = 3−5). As determined by a one-way ANOVA using Dunnett’s multiple comparison test, no
signiﬁcant inhibition was obtained with compound 14 as compared to the control (total binding); ns: not signiﬁcant, **p < 0.01. (B)
Representative microscopy images of neutrophils recovered in the lower compartment of the chemotactic chamber with WKYMVM (50 nM; left)
or compound 14 (100 nM; right) present below the ﬁlter. (C) Number of neutrophils recovered in the lower compartment with WKYMVM (50
nM) or diﬀerent concentrations of compound 14 (10−250 nM) is expressed in percent of the number of neutrophils in response to the FPR1
agonist fMLF (10 nM). The number of neutrophils recovered in the absence of any agonist (spontaneous migration) is also shown for comparison
(mean ± SD, n = 3). As determined by a one-way ANOVA using Dunnett’s multiple comparison test, no signiﬁcant increase in migration was
obtained with compound 14 as compared to no agonist; ns: not signiﬁcant, ***p < 0.001.
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overexpressing cells, WKYMVM (at 25 nM) proved capable of
β-arrestin recruitment, suggesting that FPR2 is properly
expressed, and that the system to recruit β-arrestin upon
stimulation is intact in these cells (Figure 8D). In contrast,
compound 14 failed to induce β-arrestin recruitment even at
concentrations that induced maximal superoxide release;
however, this was not due to adverse eﬀects on the cells
caused by the peptidomimetics because the cells treated with
14 proved to be viable (see Supporting Information, Figure
S3).
Overall these ﬁndings demonstrate that both WKYMVM (a
conventional FPR2 agonist) and the FPR2-activating peptido-
mimetics trigger a G-protein-dependent Ca2+ response,
whereas only binding of WKYMVM to FPR2 results in β-
arrestin recruitment. Thus, the peptidomimetic agonists (e.g.,
2, 5, and 14) exhibited biased FPR2 signaling (see Supporting
Information, Figure S1), and thus, these compounds share this
signaling property with FPR2-activating pepducins such as
F2Pal10.
16 Interestingly, biased FPR agonism has been
proposed as a new approach in the therapy for myocardial
injury.37
Notably, despite the fact that β-arrestin was not recruited by
FPR2 when triggered by these peptidomimetic agonists, the
activated receptor is rapidly desensitized after activation
(Figure 4). This is in line with reports showing that FPR
desensitization is achieved primarily through a cytoskeleton-
dependent process in which polymerized actin replaces β-
arrestin, thereby segregating the agonist-bound receptor from
the signaling G-protein.16,38,39 Even though the precise signals
involved in receptor cross-talk remain unknown, we show that
neutrophils desensitized with the lipidated peptidomimetic 14
can be reactivated to produce substantial amounts of
superoxide anions when PAFR or P2Y2R is triggered by PAF
or ATP, respectively.
Peptidomimetic 14 Is Not a Chemoattractant and
Does Not Compete in Binding with the FPR2-Selective
Agonist WKYMVM. To further elucidate key features
regarding the mechanism for neutrophil activation/desensitiza-
tion/reactivation induced by 14, binding experiments were
performed by using a ﬂuorescently labeled peptide agonist for
FPR2. As expected, nonlabeled WKYMVM in excess (i.e., the
ratio between nonlabeled and labeled peptide was 100:1)
reduced Cy5-WKYMVM binding signiﬁcantly (Figure 9A),
whereas no signiﬁcant reduction of binding was obtained with
14 in concentrations up to 1 μM (i.e., nonlabeled 14 to Cy5-
WKYMVM in the ratio 1000:1; Figure 9A). These ﬁndings
corroborate previously reported data, inferring that binding of
the ﬂuorophore-labeled FPR2-selective Cy5-WKYMVM ligand
cannot be competitively displaced by compound 2.17 We have
previously identiﬁed F2Pal10 as a biased FPR2 agonist, which
lacks the capacity to recruit β-arrestin and is devoid of
chemotactic properties.16 To investigate whether compound
14 possessed the same activation proﬁle, the ability of
compound 14 to trigger a chemotactic response in neutrophils
was determined. In contrast to WKYMVM (a positive control),
compound 14 did not induce any chemotactic migration
(Figure 9B,C).
Clearly, FPR2 has a broad ligand recognition proﬁle, as it
displays high aﬃnity for the microbial/mitochondrial formyl
peptide molecular pattern, but, on the other hand, it is
promiscuous as it accommodates binding of several other types
of ligands that may activate the receptor or inhibit receptor
function. Although the precise binding pocket for the well-
characterized FPR2 ligands has not yet been clearly deﬁned, it
is now apparent that biased agonists may stabilize receptors in
conformations diﬀerent from that triggered by conventional
agonists. Hence, these diﬀerent subactive conformations
appear to trigger distinct sets of signaling modes (e.g., G-
protein-dependent and/or β-arrestin-dependent), leading to
selective induction of certain cellular responses.10,15,40 The
present data indicate that WKYMVM and peptidomimetic
ligands (such as 14) may utilize diﬀerent binding sites and that
the peptidomimetic ligands may act as allosteric agonists.
Furthermore, this diﬀerence in binding-site occupancy may
contribute to the characteristic FPR2-mediated signaling
properties exerted by each of these ligand types.
Indeed, it would be interesting to compare the in vivo eﬀects
of biased and nonbiased agonists in models of infectious and/
or inﬂammatory diseases to delineate the contribution of these
diﬀerent FPR-dependent signaling pathways and cellular
responses to induction and resolution of inﬂammation, and
thus the therapeutic potential of targeting these pathways.
However, for such a comparison to be accurate, biased and
nonbiased agonists should preferably belong to the same
compound type to ensure similar biodistribution and stability.
Thus, future development of non-biased FPR2-selective
agonists belonging to the present class of peptidomimetics
would allow for a delineation of the molecular requirements for
induction of β-arrestin recruitment and chemotaxis, which
both are highly relevant signaling properties.
■ CONCLUSIONS
Regarding FPR2 activation and inhibition by lipidated α-
peptide/β-peptoid hybrids, the present study provides
structural insights into the critical role of the two residues
vicinal to the N-terminal hydrophobic headgroup as well as the
eﬀects of presence/absence of α-chirality in the peptoid
residues of the tail region. These peptidomimetics constitute a
lipidated subclass of α-peptide/β-peptoid hybrids, which
earlier were found to resist proteolytic degradation by
generalist enzymes such as pronase and speciﬁc enzymes
such as trypsin and chymotrypsin.8,9 Also, these FPR2-selective
agonists were found to exert biased signaling and mediate
functional selectivity in human neutrophils. Nevertheless,
further studies are required to elucidate the exact role of β-
arrestin in signaling, causing a reactivation of desensitized
FPRs. In summary, these proteolytically stable peptidomi-
metics with unique signaling properties may constitute
excellent tools for elucidating the mechanistic details in
FPR2-mediated signaling as well as for disclosing its
immunoregulatory function in vivo. In addition, future studies
should also increase our understanding of the impact of these
novel FPR2 ligands on other cells that endogenously express
FPR2.
■ EXPERIMENTAL SECTION
Materials. Solvents, Fmoc-protected amino acid building
blocks, Rink amide resin, and coupling reagents were
purchased from IrisBiotech (Marktredwitz, Germany), while
Lau-OSu, decanoic acid, and myristic acid were from Sigma-
Aldrich Chemie (Steinheim, Germany). Dextran and Ficoll−
Paque were obtained from GE-Healthcare Bio-Science
(Uppsala, Sweden). Horseradish peroxidase (HRP) was
obtained from Boehringer Mannheim (Germany). The
hexapeptide WKYMVM was obtained from AltaBioscience
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(University of Birmingham, Birmingham, UK), and the PIP2-
binding peptide PBP10 was obtained from Caslo Laboratory
(Lyngby, Denmark). Isoluminol, fMLF, bovine serum albumin
(BSA), TNF-α, and ATPγS were obtained from Sigma (Sigma
Chemical Co., St. Louis, MO, USA). Fura-2 was from
Molecular Probes, while Cy5-WKYMVM was from Phonenix
Pharmaceutical (Burlingame, CA). Cyclosporin H (CysH) was
kindly provided as a gift from Novartis Pharma (Basel,
Switzerland), while PAF was obtained from Avanti Polar Lipids
Inc. (Alabama, USA). Peptide stock solutions were prepared in
dimethyl sulfoxide and stored at −70 °C until use.
Subsequently, all dilutions of reagents were made with
Krebs−Ringer phosphate buﬀer (KRG, pH 7.3; 120 mM
NaCl, 5 mM KCl, 1.7 mM KH2PO4, 8.3 mM NaH2PO4, and
10 mM glucose) supplemented with Ca2+ (1 mM) and Mg2+
(1.5 mM).
General Methods for Compound Characterization.
The identity of compounds was determined by high-resolution
mass spectrometry, while purity was measured by ultrahigh-
performance liquid chromatography (UHPLC) to be at least
97% (detection at λ = 220 nm). Analytical UHPLC was
performed on a Shimadzu Prominence UHPLC system by
using a Phenomenex Luna C18(2) HTS column (100 × 3.0
mm; particle size: 2.5 μm), eluted at a rate of 0.5 mL/min.
Injection volumes were 5−10 μL of ∼1 mg/mL solutions.
Separations were performed at 40 °C. Eluents: A [H2O/
acetonitrile (MeCN)/triﬂuoroacetic acid (TFA) 95:5:0.1] and
B (MeCN/H2O/TFA 95:5:0.1) were used for all peptidomi-
metics in a linear gradient of 20% B → 80% B during 10 min.
Separation by preparative HPLC was performed on a
Phenomenex Luna C18(2) column (250 × 21.2 mm; particle
size: 5 μm) on a Shimadzu system composed of a CBM-20A
Prominence communication bus module, two LC-20AP
Prominence pumps, an SPD-M20A Prominence diode array
detector, and an SIL-20A HT Prominence autosampler. The
above eluents A and B were employed with a ﬂow rate of 20
mL/min; injection volumes were 300−900 μL, and a linear
gradient of 20% B → 80% B during 20 min was employed.
High-resolution MALDI-TOF spectra were obtained on a
Bruker SolariX XR in MALDI mode giving (m/z): [M + H]+
for all peptidomimetics with ΔM below 5 ppm.
Synthesis of Peptidomimetics. Peptidomimetics 5−10
and 12−25 were prepared by using standard Fmoc-based
solid-phase synthesis in Teﬂon reactors (10 mL): a Rink amide
resin (loading, 0.5−0.7 mmol/g; 0.05−0.1 mmol scale) and
corresponding dimeric building blocks were employed.17,41
Removal of Fmoc protecting groups was performed with 20%
piperidine in N,N-dimethylformamide (DMF, 2 × 10 min,
each with 5 mL, including a 1 min wash with DMF in
between). After the third coupling and henceforth, Fmoc
removal was performed in the following way: 20% piperidine in
DMF (2 × 5 min, each with 5 mL; with a 1 min DMF wash in
between) and 2% DBU +2% piperidine in DMF (2 × 5 min,
each with 5 mL; with 1 min DMF wash in between). Upon
completing each coupling, the resin was washed with DMF,
MeOH, and dichloromethane (DCM, 3 × 2 min, each with 5
mL), and after Fmoc deprotection, it was washed with DMF,
MeOH, and DCM (3 × 3 min, each with 5 mL). The building
blocks (3 equiv) were coupled by using PyBOP (3 equiv) and
diisopropylethylamine (DIPEA, 6 equiv) in DMF (1.5−3 mL)
under shaking at room temperature for at least 2 h. Upon the
fourth coupling and henceforth, capping with Ac2O/DIPEA/
NMP 1:2:3 (5 mL, 10 min) was applied. After assembly of the
peptidomimetic tail region, the N-terminus was functionalized
via coupling of Fmoc-Aoc-OH (5 equiv) for 16 h. After the last
Fmoc removal, acylation was performed with decanoic acid or
myristic acid with PyBOP (5 equiv) as the coupling reagent or
via coupling with Lau-OSu (5 equiv, 16 h; 5 equiv DIPEA).
Finally, the peptidomimetics were cleaved from the resin by
using TFA−water 95:5 (5 mL, 1 h at room temperature).
Following evaporation in vacuo, the resulting residues were
puriﬁed by preparative HPLC. Upon lyophilization, the target
compounds were stored at −20 °C until use.
Peptidomimetic 5. Gradient: 20→ 80% B over 10 min. B =
95% MeCN + 0.1% TFA. tR = 6.29 min. MALDI−TOF: calcd
for [M + H]+, 2161.4873; found, 2161.4882; ΔM = 0.4 ppm.
Peptidomimetic 6. Gradient: 20→ 80% B over 10 min. B =
95% MeCN + 0.1% TFA. tR = 5.71 min. MALDI−TOF: calcd
for [M + H]+, 2133.4560; found, 2133.4532; ΔM = 1.3 ppm.
Peptidomimetic 7. Gradient: 20→ 80% B over 10 min. B =
95% MeCN + 0.1% TFA. tR = 6.94 min. MALDI−TOF: calcd
for [M + H]+, 2189.5195; found 2189.5167; ΔM = 1.2 ppm.
Peptidomimetic 8. Gradient: 20→ 80% B over 10 min. B =
95% MeCN + 0.1% TFA. tR = 6.46 min. MALDI−TOF: calcd
for [M + H]+, 2161.4873; found 2161.4860; ΔM = 0.6 ppm.
Peptidomimetic 9. Gradient: 20→ 80% B over 10 min. B =
95% MeCN + 0.1% TFA. tR = 5.86 min. MALDI−TOF: calcd
for [M + H]+, 2133.4560; found 2133.4564; ΔM = 0.1 ppm.
Peptidomimetic 10. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 7.07 min. MALDI−TOF:
calcd for [M + H]+, 2189.5187; found 2189.5183; ΔM = 0.1
ppm.
Peptidomimetic 12. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.31 min. MALDI−TOF:
calcd for [M + H]+, 2161.4873; found 2161.4913; ΔM = 1.8
ppm.
Peptidomimetic 13. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.45 min. MALDI−TOF:
calcd for [M + H]+, 2161.4873; found 2161.4843; ΔM = 1.3
ppm.
Peptidomimetic 14. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.13 min. MALDI−TOF:
calcd for [M + H]+, 2091.4091; found, 2091.4091; ΔM = 0.0
ppm.
Peptidomimetic 15. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.21 min. MALDI−TOF:
calcd for [M + H]+, 2091.4091; found, 2161.4193; ΔM = 4.8
ppm.
Peptidomimetic 16. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.13 min. MALDI−TOF:
calcd for [M + H]+, 2163.3778; found, 2163.3763; ΔM = 0.6
ppm.
Peptidomimetic 17. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 5.79 min. MALDI−TOF:
calcd for [M + H]+, 2079.3727; found, 2079.3722; ΔM = 0.2
ppm.
Peptidomimetic 18. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.15 min. MALDI−TOF:
calcd for [M + H]+, 2102.3887; found, 2102.3873; ΔM = 0.6
ppm.
Peptidomimetic 19. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.23 min. MALDI−TOF:
calcd for [M + H]+, 2049.3621; found, 2049.3603; ΔM = 0.8
ppm.
Peptidomimetic 20. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.27 min. MALDI−TOF:
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calcd for [M + H]+, 2035.3465; found, 2035.3471; ΔM = 0.2
ppm.
Peptidomimetic 21. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 5.96 min. MALDI−TOF:
calcd for [M + H]+, 2063.3778; found, 2063.3779; ΔM = 0.1
ppm.
Peptidomimetic 22. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.05 min. MALDI−TOF:
calcd for [M + H]+, 2077.3934; found, 2077.3919; ΔM = 0.7
ppm.
Peptidomimetic 23. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.02 min. MALDI−TOF:
calcd for [M + H]+, 2077.3934; found, 2077.3940; ΔM = 0.2
ppm.
Peptidomimetic 24. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 7.44 min. MALDI−TOF:
calcd for [M + H]+, 2048.3669; found, 2048.3690; ΔM = 1.0
ppm.
Peptidomimetic 25. Gradient: 20 → 80% B over 10 min. B
= 95% MeCN + 0.1% TFA. tR = 6.25 min. MALDI−TOF:
calcd for [M + H]+, 2091.3839; found, 2091.3843; ΔM = 0.1
ppm.
Ethics Statement. In the present study, conducted at the
Sahlgrenska Academy, Gothenburg, Sweden, we used buﬀy
coat preparations that were obtained from the blood bank at
Sahlgrenska University Hospital, Gothenburg, Sweden. Ac-
cording to Swedish legislation section code 4§ 3p SFS
2003:460 (Lag om etikprövning av forskning som avser
man̈niskor), no ethical approval was required because the
buﬀy coats were provided anonymously and thus could not be
traced back to a speciﬁc donor.
Isolation of Human Neutrophils. Peripheral blood
neutrophils were isolated from human buﬀy coats from healthy
blood donors by using a dextran sedimentation and Ficoll/
Paque gradient centrifugation: the cell-rich plasma/buﬀy coat
was mixed with physiological saline containing dextran (2% w/
v; MW 500 000), and then sedimentation of erythrocytes was
allowed to take place for 30 min at ambient temperature. The
leucocyte-enriched plasma/buﬀy coat was layered onto a
Ficoll/Paque solution (density of 1.077 g/mL) and centrifuged
for 15 min (930g; 4 °C).42 The remaining erythrocytes in the
neutrophil pellet were subjected to hypotonic lysis, and then
upon washing, the neutrophils were resuspended in KRG and
stored on melting ice until use. This isolation procedure allows
for cell puriﬁcation with minimal granule mobilization.
Neutrophil NADPH Oxidase Activity. NADPH oxidase
activity was measured in an isoluminol-enhanced chemilumi-
nescence (CL) assay: neutrophils were added to a 4 mL
polypropylene tube containing isoluminol (2 × 10−5 M) and
HRP (2U) in KRG (ﬁnal volume 900 μL).43,44 The tubes were
subjected to equilibration in the Biolumat for 5 min at 37 °C,
after which the stimulating agent (100 μL) was added, and
then light emission was recorded continuously. Receptor
reactivation and cross-talk were achieved by initial stimulation
of cells by exposure to a receptor-speciﬁc agonist, and when
the response returned to baseline (i.e., the desensitized state),
the cells were reactivated by receiving a second stimulation to
induce release of superoxide. In these reactivation experiments,
the antagonists were added to the CL assay mixture 1 min
prior to the second stimulation. The CL response was
measured with a six-channel Biolumat LB 9505 (Berthold
Co., Germany).
β-Arrestin Recruitment Assay. The capability of FPR2
agonists to promote recruitment of β-arrestin was evaluated in
PathHunter eXpress CHO-K1 FPR2-overexpressing cells from
DiscoverX (Fremont, USA). The CHO-K1 cells coexpress β-
arrestin (isoform 2) tagged with an EA of β-galactosidase and
FPR2 tagged with the complementary part (PK) of the β-
galactosidase enzyme. Thus, activation of FPR2-PK induces β-
arrestin-EA recruitment, forcing complementation of the two
β-galactosidase EAs, leading to the assembly of a functional
enzyme capable of hydrolyzing the substrate, thereby
generating a CL signal. The CHO-K1 cells were seeded into
96-well plates at a density of 10 000 cells/well, which were
then grown for 24 h at 37 °C in 5% CO2. The overnight-
cultured cells were activated with agonists and allowed to
recruit β-arrestin for 90 min at 37 °C, after which a CL-based
detection solution was added (DiscoverX), and then enzyme
activity was determined. Light generation, given as relative CL
units, was measured with a Multilabel Microtiter Plate Reader
(Clariostar, BMG Labtech, Germany).16
Calcium Mobilization. Freshly isolated neutrophils in
KRG containing 0.1% BSA (5 × 107 cells/mL) were exposed
to 5 μM FURA 2-AM for 30 min in the dark at room
temperature according to the supplier’s protocol (Thermo-
Fisher, USA). The cell suspensions were then diluted 1:2 with
RPMI 1640 culture medium without phenol red (PAA
Laboratories GmbH, Pasching, Austria), and the resulting
suspensions were then centrifuged. Next, the cells were washed
once with KRG and were resuspended in KRG to yield a
density of 2 × 107 cells/mL. The FURA 2-labeled neutrophils
were added to a polystyrene cuvette that was equilibrated in
the ﬂuorometer for 10 min at 37 °C, upon which the
stimulatory agent (100 μL) was added, and then ﬂuorescence
was recorded continuously. These measurements were
performed with a PerkinElmer ﬂuorescence spectrophotometer
(LC50) having excitation wavelengths set to 340 and 380 nm,
an emission wavelength set to 509 nm, and slit widths of 5 and
10 nm, respectively. The transient increase in the intracellular
Ca2+ level is presented as the ratio between the ﬂuorescence
intensities detected (i.e., 340 nm: 380 nm).
Evaluation of Ligand−Receptor Binding by Flow
Cytometry. Neutrophils suspended in ice-cold KRG (1 ×
106 cells/mL) were preincubated with unlabeled ligands for 10
min while being kept on ice. A ﬂuorophore-labeled FPR2-
selective agonist (Cy5-WKYMWM; 1 nM ﬁnal concentration)
was added, and then incubation on ice was continued for an
additional 60 min. Binding of the ﬂuorescent FPR2 agonist to
the neutrophils was then analyzed by ﬂow cytometry by using
the settings for the Cy5 ﬂuorophore (Ex 488 nm/Em 670 nm).
For each sample, 10 000 cells were collected by using an Accuri
C6 ﬂow cytometer (Becton Dickinson Sparks, MD, USA).
Neutrophil samples incubated with Cy5-WKYMVM, either
alone or in combination with WKYMVM (100 nM ﬁnal
concentration), were included as controls to determine total
binding (Cy5-WKYMVM alone) and nonspeciﬁc binding
(labeled and unlabeled WKYMVM together), respectively.
Stability of Receptor Ligands to MPO−H2O2-Medi-
ated Oxidation. In order to investigate the sensitivity of the
FPR2 agonists WKYMVM and peptidomimetic 14 to MPO−
H2O2-mediated oxidation, the agonists (1 μM concentration)
were incubated with MPO (1 μg/mL; 5 min 37 °C) prior to
addition of H2O2 (ﬁnal concentration, 10 μM). The samples
were incubated for an additional 10 min at room temperature.
Agonists incubated under the same conditions, but without
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MPO and H2O2, were used as controls. The remaining activity
of the agonists (WKYMVM and 14) was determined by their
ability to induce neutrophil NADPH oxidase activity as
described above.
Neutrophil Chemotaxis. Neutrophil chemotaxis was
determined in a ﬁlter assay system (ChemoTx, Neuro probe,
UK) used essentially as recommended by the manufacturer. In
short, neutrophils suspended in KRG supplemented with BSA
(0.3% v/w) were added on top of the ﬁlter (pore size: 3 μm),
and then cell migration was allowed to proceed for 90 min in a
cell culture incubator (at 37 °C under 5% CO2) in response to
diﬀerent receptor agonists present in the lower compartment
separated from the cells by the ﬁlter. The number of
neutrophils recovered in the lower chamber was determined
through the measurement of the MPO activity.45 The FPR
agonists fMLF (10 nM) and WKYMVM (50 nM) were used as
positive controls, while buﬀer was used as a negative control
(i.e., spontaneous migration).
Data Analysis. Data analysis was carried out with
GraphPad Prism 7.0 (Graphpad Software, San Diego, CA,
USA). Curve ﬁtting was performed by nonlinear regression
using the sigmoidal dose−response equation (variable-slope).
One-way ANOVA and Dunnett’s multiple or paired Student’s
t-test were employed for statistical analysis, and the method
used is given in the ﬁgure legends; *p < 0.05, **p < 0.01, ***p
< 0.001. Each independent experiment was performed with
neutrophils isolated from diﬀerent individual blood donors or
cell lines obtained after diﬀerent passages.
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■ ABBREVIATIONS
βNLys, N-aminobutyl-β-alanine; βNPhe, N-phenylmethyl-β-
alanine; βNrpe, N-(R)-1-phenylethyl-β-alanine; βNspe, N-(S)-
1-phenylethyl-β-alanine; Aoc, 2-aminooctanoic acid; BSA,
bovine serum albumin; CHO, chinese hamster ovary; CL,
chemiluminescence; Cy5, cyanine-5; CysH, cyclosporine H;
Dab, (S)-2,3-diaminobutanoic acid; Dec, decanoyl; DCM,
dichloromethane; DIPEA, diisopropylethylamine; DMF, N,N-
dimethylforamide; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene;
FPR, formyl peptide receptor; Fmoc, ﬂuoren-9-yl-methylox-
ycarbonyl; Fura-2 AM, Fura-2 acetoxymethyl ester; GPCR, G-
protein-coupled receptor; HRP, horseradish peroxidase; IP3,
inositol trisphosphate; KRG, Krebs−Ringer phosphate buﬀer
supplemented with glucose; Lau, lauroyl; MPO, myeloperox-
idase; Myr, myristoyl; NADPH, nicotinamide adenine
dinucleotide phosphate; Nle, norleucine; NMP, N-methyl-2-
pyrrolidone; OSu, N-oxy-succinimidyl; P2RY2, purinergic
receptor P2Y2; Pam, palmitoyl; PAF, platelet-activating factor;
PAFR, platelet-activating factor receptor; PIP2, phosphatidyli-
nositol 4,5-bisphosphate; PLC, phospholipase C; PyBOP,
(benzotriazol-1-yloxy)tripyrrolidinophosphonium hexaﬂuoro-
phosphate; RhB, rhodamine B; RPMI, Roswell Park Memorial
Institute; TFA, triﬂuoroacetic acid; TNF-α, tumor necrosis
factor α; UHPLC, ultrahigh-performance liquid chromatog-
raphy
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